Reduced risk of Alzheimer’s disease associated with diabetes target proteins

Washington [US], June 3 (ANI): Studies by researchers at the Karolinska Institute in Sweden suggest that mechanisms associated with certain diabetes drugs may also help protect against Alzheimer’s disease. An interesting candidate for the treatment of Alzheimer’s disease.

Alzheimer’s disease is becoming more and more common, but there are no drugs that affect the course of the disease, and new drug development is a slow, costly, and complex process.

Therefore, another strategy is to find already approved medicines that have proven effective against the disease and can give them new areas of application. Diabetes treatments have been proposed as candidates, but so far, studies testing diabetes treatments for Alzheimer’s disease have not yielded convincing results.

In this study, researchers at the Karolinska Institute used genetic techniques to study this more closely.

“Gene mutations in or near the gene encoding the target protein of the drug can cause physiological changes similar to the effects of the drug,” said the lead author of the study, Medical Epidemiology and Biology at the Karolinska Institute. Bowen Tang, a PhD student in the Faculty of Statistics, said. “We use such variants to test the potential for diversion of already approved drugs.” Researchers mimic the pharmacological effects of diabetes drugs, namely lowering blood sugar levels. I started by identifying the genetic variants that I would like to have. This was done through the analysis of data from more than 300,000 participants in the UK Biobank register.

The analysis identified variants of two genes that together encode a target protein in a class of diabetes drugs called sulfonylureas. Researchers have validated these mutations by showing an association with increased insulin release, reduced risk of type 2 diabetes, and increased BMI, among other phenomena. This is consistent with the effect of the drug.

Next, the researchers investigated the association between the identified genetic variation and the risk of Alzheimer’s disease. They did this by analyzing data previously collected from more than 24,000 people with Alzheimer’s disease and 55,000 controls. They found that genetic variation of the sulfonylurea gene was associated with a reduced risk of Alzheimer’s disease.

“Our results suggest that the KATP channel, a target protein for sulfonylureas, may be a therapeutic target for the treatment and prevention of Alzheimer’s disease,” said the final author of this study. Sarah Hugg of the Department of Medical Epidemiology and Biostatistics at the Karolinska Institute said. .. “This protein is expressed not only in the pancreas but also in the brain, and further research is needed to fully understand the underlying biology.” (ANI) Reduced risk of Alzheimer’s disease associated with diabetes target proteins

Back to top button